All Outputs (3)

Chloride co-transporters as possible therapeutic targets for stroke (2016)
Journal Article
Martín-Aragón Baudel, M. A. S., Martín-Aragón Baudel, M. A. S., Poole, A. V., & Darlison, M. G. (2017). Chloride co-transporters as possible therapeutic targets for stroke. Journal of Neurochemistry, 140(2), 195-209. https://doi.org/10.1111/jnc.13901

Stroke is one of the major causes of death and disability worldwide. The major type of stroke is an ischaemic one, which is caused by a blockage that interrupts blood flow to the brain. There are currently very few pharmacological strategies to red... Read More about Chloride co-transporters as possible therapeutic targets for stroke.

Investigating the molecular mechanisms driving neuroendocrine differentiation in androgen deprived prostate cancer cells (2016)
Conference Proceeding
Sutton, J., Hutchison, G., Fraser, J., & Poole, A. (2016). Investigating the molecular mechanisms driving neuroendocrine differentiation in androgen deprived prostate cancer cells

Background: Neuroendocrine differentiation is commonplace in prostate tumors treated with androgen deprivation therapy and is associated with castrate-resistant disease progression and poor prognosis. The molecular mechanisms driving neuroendocrine d... Read More about Investigating the molecular mechanisms driving neuroendocrine differentiation in androgen deprived prostate cancer cells.

Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer (2016)
Journal Article
Mathur, S., Mincher, D., Turnbull, A., Stevens, C., & Poole, A. (2016). Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer. European Journal of Cancer, 61, S142. https://doi.org/10.1016/s0959-8049%2816%2961501-0

Background: In spite of major advances in the diagnosis and treatment of cancer, there remains a paucity of biomarkers for early detection. Legumain is a potential cancer biomarker and a molecular target for imaging and drug targeting. Legumain is a... Read More about Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer.